famotidine has been researched along with Cardiomyopathies in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
Excerpt | Relevance | Reference |
---|---|---|
" Dexrazoxane is approved to combat the cardiotoxicity, but limited by its adverse effects." | 1.48 | Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model. ( Allakonda, L; Kondru, SK; Konduri, P; Potnuri, AG, 2018) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kondru, SK | 1 |
Potnuri, AG | 1 |
Allakonda, L | 1 |
Konduri, P | 1 |
1 other study available for famotidine and Cardiomyopathies
Article | Year |
---|---|
Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model.
Topics: Animals; Apoptosis; Cardiomyopathies; Doxorubicin; Famotidine; Histamine H2 Antagonists; Male; Muscl | 2018 |